

# Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42<sup>th</sup> Annual J.P. Morgan Healthcare Conference.

## Conference Details:

### *Presentation and Q&A*

Date: Monday, January 8, 2024  
Time: 5:15 – 5:55 p.m. Pacific Standard Time (PST)  
Location: Westin St. Francis Hotel in San Francisco, California  
Moderator: Eric Joseph, Ph.D., Executive Director, Biotechnology Equity Research  
Novavax participants: John C. Jacobs, President and Chief Executive Officer

### *Conference*

Event: Investor Meetings  
Date: Monday, January 8, 2024

## Recordings

A replay of the recorded presentation and Q&A will be available through the Events & presentations page of the Company's website at [ir.novavax.com](http://ir.novavax.com) for 30 days from the date of the conference.

## About Novavax

Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit [novavax.com](http://novavax.com) and [LinkedIn](#) for more information.

## Contacts:

### Investors

Erika Schultz  
240-268-2022  
[ir@novavax.com](mailto:ir@novavax.com)

### Media

Ali Chartan  
240-720-7804  
[media@novavax.com](mailto:media@novavax.com)

SOURCE NOVAVAX, INC